Edgewood Oncology’s Post

🇺🇸🔬 #ASCO2024 | A few takeaways from the American Society of Clinical Oncology (ASCO) Annual Meeting on lung cancer, breast cancer, hepatocellular carcinoma, and melanoma. This confirms high unmet needs where XENOTHERA’s XON7 could bring strong benefits.   👉 For more information on XON7, please refer to our latest press release « XENOTHERA reports to ASCO on the clinical trial of its first anti-cancer drug, XON7, and announces a financing agreement with BPI France » :  https://lnkd.in/eFxHhU6V   #CancerResearch #Treatment #Oncology #Biotech #Immunotherapy

++ Head-to-head comparison of treatment sequences in advanced pancreatic cancer ++ As there are no studies that directly compare treatment sequences for advanced pancreatic cancer, no treatment guidelines can be defined. In order to obtain information on the optimal treatment sequence, we compared the data of 1,551 patients from our prospective pancreatic cancer tumour registry. The results show that the efficacy of the three compared sequences is similar. Poor-risk patients might benefit from intensified treatment with FOLFIRINOX --> GEMNAB. To identify the optimal treatment sequence, randomised studies on sequential therapy in pancreatic cancer are required in the future. Please find the full publication in the first comment below this article. #pancreas #pancreaticcancer #RWD #realworlddata #oncology

🌟 Thrilled to announce the publication of our latest article, exploring the groundbreaking antitumor potential of Guttiferone E in combination with Carboplatin against Osimertinib-resistant H1975 lung cancer! This research delves into the mechanisms by which this powerful duo triggers apoptosis in resistant cancer cells, paving the way for innovative treatment strategies that could transform patient outcomes. I invite you to read the full article and engage in a conversation about the future of lung cancer therapies. Your insights and feedback would be greatly appreciated! Link to the article: https://lnkd.in/ehhf_WhV #LungCancer #CancerResearch #InnovativeTherapies #Oncology #GuttiferoneE #Pharmacology #NaturalCompounds #Brazil #AnticancerResearch #FAMU #PhD

🔬 Highlights from ASCO 2024 on prostate cancer 🔬 presented by Prof Dr Piet Dirix from the Iridium Network in Antwerp, Belgium. - the HERCULES trial evaluated the efficacy of first-line cisplatin-based chemotherapy combined with pembrolizumab in patients with penile cancer. - the NEPTUNES trial  focused on immunotherapy for highly immunogenic subtypes of metastatic prostate cancer.  - New Drugs for mCRPC, JNJ-6420 and ARV-766 - Tarlatamab in mCRPC patients with neuroendocrine differentiation. - PSMA-PET as a predictor of OS Stay updated on the latest research findings in prostate cancer by watching this episode! Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #ASCO2024 #ProstateCancer #CancerResearch #Oncology #MediMix

🌟 Last Call for Enrollment! 🌟 Don't miss the October 31st deadline to enroll in Champions' Pancreatic Cancer TumorGraft3D Screen! This premier 3D ex vivo screening is designed to evaluate therapies for pancreatic cancer. Enroll Today: https://hubs.li/Q02T9dJr0 Our screen features rare 3D organ-like tumor models derived from low-passaged PDX models, accurately replicating the cellular diversity and microenvironment of tumors. By using 3D organoids with critical mutations like KRAS G12D, G12V, and G12R, we aim to provide insights that truly reflect patient responses in clinical settings. #pancreaticcancer #exvivo #oncologyresearch #cancerresearch #oncology #cancer #3Dtumormodels #coculture #tumorgraft3d #organoid

🌟 Exploring Evolving Strategies for HR-Positive Breast Cancer with Dr. Virginia Kaklamani 🩺 In a recent interview, Dr. Virginia Kaklamani discussed the rapidly advancing landscape of hormone receptor-positive breast cancer treatments. With the emergence of novel medications like CDK4-6 inhibitors, oral SERDs, and PI3K/AKT pathway inhibitors, she emphasized the need for NGS testing to guide treatment decisions. Dr. Kaklamani highlighted the unique efficacy and safety profiles of alpelisib, inovolacib, and capivacertib, and provided insights on selecting the most suitable therapy based on specific genetic mutations. Learn more about her expert perspectives on optimizing patient outcomes in metastatic breast cancer! 💡 #BreastCancer #Oncology #HRPositive #EndocrineResistance #CancerResearch #OncologyFrontier

Non-Small Cell Lung Cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, making it the most common type of lung cancer. Key subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Interestingly, NSCLC is highly associated with specific genetic mutations like EGFR and ALK, opening the door to precision therapies that can target these changes. Early diagnosis and targeted treatments can greatly improve outcomes. Stay informed on the latest advancements. Follow LARVOL for updates on clinical trials, treatments, and oncology conferences. #NSCLC #LungCancer #Oncology #ClinicalTrials #LARVOL #WCLC2024 #ESMO2024

My FDA Oncology Round Up for September It was a busy month for the FDA with 7 approvals! In this quick video, I highlight a few of them and why they matter, including breakthroughs in lung cancer, breast cancer, and mesothelioma.   Key highlights: –         Practice-changing approval for Osimertinib in locally advanced EGFR+ lung cancer –         New adjuvant therapy option for early-stage ER+/HER2- breast cancer –         Frontline combination therapy approval for malignant pleural mesothelioma Do you agree these latest approvals will have an impact on patients and drug developers?   #FDA #Oncology #ClinicalTrials 

Cyclacel Pharmaceuticals, Inc. completes enrollment in the biomarker-enriched patient cohort of its Phase 2 study of fadraciclib, a CDK2/9 inhibitor, targeting advanced solid tumors and lymphoma. This cohort focuses on patients with CDKN2A and/or CDKN2B abnormalities. An update will be presented at ENA 2024. Learn more: https://bit.ly/47GNMUs EORTC - European Organisation for Research and Treatment of Cancer, American Association for Cancer Research, National Cancer Institute (NCI) #ENASymp24 #Oncology #CancerResearch

⚡Leverage Champions’ 80+ Pancreatic Cancer PDX models⚡ Including several pretreated models and different KRAS mutations such as Gly12Arg, Gly12Asp, Gly12Val. Our Pancreatic PDX bank gives you access to deeply characterized and clinically annotated models to accelerate your oncology programs. Learn more: https://hubs.li/Q02TSbg80 Enroll in our new Pancreatic Cancer TumorGraft3D Screen: https://hubs.li/Q02TSlDl0 #PancreaticCancer #organoids #3Dcultures #3Dtumormodels #PDX #PDXmodels #PDAC #oncology #oncologyresearch #cancer #cancerresearch #Gly12Arg #Gly12Asp #Gly12Val #KRAS